Although HER2-positive gastric cancers represent the minority of the overall patient population, it defines a subset of patients with an actionable molecular alteration—a rarity in the landscape of a tumour type where the development of targeted therapies has been disadvantaged by molecular heterogeneity. This evidence concerns the gene ERBB2 and gastric cancer.